HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

PMDA

Regulatory intelligence
PMDAsafety guidance72% confidence

[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

Source: PMDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as BioMarin Pharmaceutical.

Regulatory Analysis

PMDA document relevant to the signal.

Supporting Context

Therapeutic area
Pediatrics · Growth Disorders
Sub-indication
Ild

Related signal: BioMarin's Study on Growth in Children with Idiopathic Short Stature Underway

Source

View source document

Related Signal

Open signal — BioMarin's Study on Growth in Children with Idiopathic Short Stature Underway
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.